Table 2 Treatment-related adverse events (AE).
Adverse event (AE) type | AE of any grade | Grade 1 AE | Grade 2 AE | Grade 3 AE | Grade 4 AE |
|---|---|---|---|---|---|
Platelet count decreased | 11(91.67%) | 5(41.67%) | 4(33.33%) | 2(16.67%) | 0(0%) |
Anemia | 10(83.33%) | 4(33.33%) | 3(25%) | 3(25%) | 0(0%) |
Neutrophil count decreased | 9(75%) | 0(0%) | 4(33.33%) | 4(33.33%) | 1(8.33%) |
White blood cell decreased | 8(66.67%) | 2(16.67%) | 2(16.67%) | 4(33.33%) | 0(0%) |
Fatigue | 7(58.33%) | 4(33.33%) | 3(25%) | 0(0%) | 0(0%) |
Aspartate aminotransferase increased | 6(50%) | 3(25%) | 2(16.67%) | 1(8.33%) | 0(0%) |
Alanine aminotransferase increased | 5(41.67%) | 3(25%) | 1(8.33%) | 1(8.33%) | 0(0%) |
Electrocardiogram QT corrected interval prolonged | 5(41.67%) | 4(33.33%) | 1(8.33%) | 0(0%) | 0(0%) |
Lymphocyte count decreased | 5(41.67%) | 2(16.67%) | 1(8.33%) | 2(16.67%) | 0(0%) |
Nausea | 5(41.67%) | 4(33.33%) | 1(8.33%) | 0(0%) | 0(0%) |
Blood bilirubin increased | 3(25%) | 2(16.67%) | 1(8.33%) | 0(0%) | 0(0%) |
Cough | 3(25%) | 3(25%) | 0(0%) | 0(0%) | 0(0%) |
Diarrhea | 3(25%) | 2(16.67%) | 1(8.33%) | 0(0%) | 0(0%) |
Epistaxis | 3(25%) | 3(25%) | 0(0%) | 0(0%) | 0(0%) |
Mucositis oral | 3(25%) | 3(25%) | 0(0%) | 0(0%) | 0(0%) |
Alkaline phosphatase increased | 2(16.67%) | 2(16.67%) | 0(0%) | 0(0%) | 0(0%) |
Bruising | 2(16.67%) | 2(16.67%) | 0(0%) | 0(0%) | 0(0%) |
Creatinine increased | 2(16.67%) | 0(0%) | 2(16.67%) | 0(0%) | 0(0%) |
Dry mouth | 2(16.67%) | 1(8.33%) | 1(8.33%) | 0(0%) | 0(0%) |
Fever | 2(16.67%) | 0(0%) | 2(16.67%) | 0(0%) | 0(0%) |
Hypophosphatemia | 2(16.67%) | 0(0%) | 1(8.33%) | 1(8.33%) | 0(0%) |
Rash maculo-papular | 2(16.67%) | 2(16.67%) | 0(0%) | 0(0%) | 0(0%) |
Vomiting | 2(16.67%) | 1(8.33%) | 1(8.33%) | 0(0%) | 0(0%) |
Weight loss | 2(16.67%) | 2(16.67%) | 0(0%) | 0(0%) | 0(0%) |
Activated partial thromboplastin time prolonged | 1(8.33%) | 0(0%) | 1(8.33%) | 0(0%) | 0(0%) |
Alopecia | 1(8.33%) | 1(8.33%) | 0(0%) | 0(0%) | 0(0%) |
Arthritis | 1(8.33%) | 1(8.33%) | 0(0%) | 0(0%) | 0(0%) |
Bloating | 1(8.33%) | 1(8.33%) | 0(0%) | 0(0%) | 0(0%) |
Constipation | 1(8.33%) | 1(8.33%) | 0(0%) | 0(0%) | 0(0%) |
Cystitis noninfective | 1(8.33%) | 1(8.33%) | 0(0%) | 0(0%) | 0(0%) |
Dry eye | 1(8.33%) | 1(8.33%) | 0(0%) | 0(0%) | 0(0%) |
Febrile neutropenia | 1(8.33%) | 0(0%) | 0(0%) | 1(8.33%) | 0(0%) |
Gastroesophageal reflux disease | 1(8.33%) | 0(0%) | 1(8.33%) | 0(0%) | 0(0%) |
Gastrointestinal disorders—other, specify | 1(8.33%) | 0(0%) | 1(8.33%) | 0(0%) | 0(0%) |
Headache | 1(8.33%) | 1(8.33%) | 0(0%) | 0(0%) | 0(0%) |
Hyperhidrosis | 1(8.33%) | 1(8.33%) | 0(0%) | 0(0%) | 0(0%) |
Hypokalemia | 1(8.33%) | 1(8.33%) | 0(0%) | 0(0%) | 0(0%) |
Infusion related reaction | 1(8.33%) | 1(8.33%) | 0(0%) | 0(0%) | 0(0%) |
Lung infection | 1(8.33%) | 0(0%) | 1(8.33%) | 0(0%) | 0(0%) |
Myalgia | 1(8.33%) | 1(8.33%) | 0(0%) | 0(0%) | 0(0%) |
Oral hemorrhage | 1(8.33%) | 1(8.33%) | 0(0%) | 0(0%) | 0(0%) |
Pain | 1(8.33%) | 1(8.33%) | 0(0%) | 0(0%) | 0(0%) |
Peripheral motor neuropathy | 1(8.33%) | 1(8.33%) | 0(0%) | 0(0%) | 0(0%) |
Renal and urinary disorders—other, specify | 1(8.33%) | 0(0%) | 0(0%) | 1(8.33%) | 0(0%) |
Salivary duct inflammation | 1(8.33%) | 1(8.33%) | 0(0%) | 0(0%) | 0(0%) |
Thrombotic thrombocytopenic purpura | 1(8.33%) | 0(0%) | 1(8.33%) | 0(0%) | 0(0%) |
Upper respiratory infection | 1(8.33%) | 0(0%) | 1(8.33%) | 0(0%) | 0(0%) |
Urinary tract infection | 1(8.33%) | 0(0%) | 0(0%) | 1(8.33%) | 0(0%) |
